SPRY — ARS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $429.61m
- $382.44m
- $84.28m
ARS Pharmaceuticals' Q3 loss widens on higher costs
Brief: ARS Pharmaceuticals Receives Favorable Decision From European Patent Office On Patent Related To Neffy® (Epinephrine Nasal Spray)
Epinephrine nasal spray maker ARS sues Aptar alleging device supply monopoly
Brief: Ars Pharmaceuticals Secures Up To $250 Million Loan Facility
U.S. STOCKS ON THE MOVE-BILL Holdings, Jackson Financial, Wills Towers Watson
U.S. STOCKS ON THE MOVE-Gold miners, Perpetua Resources, KalVista Pharmaceuticals
Brief: neffy Approved In Japan As The First Needle-Free Epinephrine Nasal Spray For Emergency Anaphylaxis Treatment
ARS Pharma up after Japan's approval for allergic reaction nasal spray
Brief: ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., As Board Chair
ARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharma rises after Q2 revenue beats estimates
ARS Pharmaceuticals Inc expected to post a loss of 47 cents a share - Earnings Preview
ARS Pharmaceuticals Inc expected to post a loss of 47 cents a share - Earnings Preview
ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million
ARS Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website
Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S
U.S. STOCKS ON THE MOVE-Accenture, Nike, FedEx